Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda Pharmaceutical Korea is supplying Replagal(agalsidase alfa)Injection domestically for patients with Fabry disease.